Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

NCT ID: NCT00948467

Last Updated: 2013-07-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-12-31
• Study Completion Date: 2013-06-30

Brief Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.

Conditions

Advanced Non-hematologic Malignancies; Advanced Metastatic Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAK-733

Group Type: EXPERIMENTAL

TAK-733

Intervention Type: DRUG

The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

Interventions

TAK-733

The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 18 years or older.
• Have one of the following diagnoses: a nonhematologic malignancy for which standard, curative, or life-prolonging treatment does not exist or is no longer effective; OR have stage 3 or stage 4 unresectable melanoma not priorly treated with either MEK or BRAF inhibitor therapy.
• Melanoma patients should have the V600E BRAF mutation status of their tumor documented, if available, and tumor tissue must be provided for confirmatory genotyping by a central laboratory.
• Have a radiographically or clinically evaluable tumor.
• Have suitable venous access for the conduct of blood sampling.
• Provide voluntary written consent, which can be withdrawn by the patient at any time.
• Female patients who: are post-menopausal for at least 1 year before screening; OR are surgically sterile; OR if they are of childbearing potential agree to practice two effective methods of birth control from the time of signing the informed consent form through 30 days after the last dose of the study drug, or agree to completely abstain from heterosexual intercourse.
• Male patients, even if surgically sterilized, must agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of the study drug; OR agree to completely abstain from heterosexual intercourse.

Exclusion Criteria

• Female patients who are lactating or have a positive serum pregnancy test during the Screening period.
• Antineoplastic therapy or radiotherapy within 21 days; or nitrosoureas of mitomycin C within 42 days
• Prior biologic or immunotherapy ≤ 4 weeks prior to enrollment.
• Grade 2 or greater unresolved toxicity (except alopecia) from previous anticancer therapy.
• Major surgery within 14 days of the first dose of the study drug.
• An active infection requiring systemic therapy; or other severe infection.
• Symptomatic brain metastases.
• Inability to meet specific laboratory test standards during the Screening period as specified in the study protocol.
• Human Immunodeficiency (HIV) positive.
• Hepatitis B surface antigen positive or active hepatitis C infection.
• Serious medical or psychiatric illness likely to interfere with the study.
• Uncontrolled cardiovascular condition.
• Abnormalities on 12-lead ECG performed within 28 days before the start of the study drug that are considered to be clinically significant or rate corrected QT interval > 470 milliseconds.
• Melanoma patients will be excluded if they have had a diagnosis with or treatment for another malignancy within 2 years of the first dose of the study drug, or have been previously diagnosed with another malignancy with any evidence of residual disease.
• Treatment with any investigational product within 28 days before the first dose of the study drug.
• A history of an ongoing or newly diagnosed eye abnormality, such as retinal or corneal pathologies.
• Abnormal left ventricular ejection fraction (LVEF).
• Receiving therapeutic anticoagulation
• Treatment with any of the following strong CYP3A inhibitors or inducers within 14 days before the first dose of study drug: ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, rifampin, rifapentine, or rifabutin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Millennium Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Millennium Pharmaceuticals, Inc.

Locations

Wayne State University Karmanos Cancer Institute

Detriot, Michigan, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Countries

United States

Other Identifiers

C20001

Identifier Type: -

Identifier Source: org_study_id